Abstract:Background. In this prospective study, we determined the frequency of opioid-related chemical coping among advanced cancer patients, as diagnosed by palliative medicine specialists. We also determined predictors for chemical coping and the concordance between the physician's diagnosis and documentation in the medical records. Patients and Methods. Palliative medicine specialists evaluated and diagnosed consecutive patients seen for chemical coping. The proportion of patients identified as chemically coping was… Show more
“…The definition used varied according to the article. Some authors consider only abuse [ 18 ], misuse [ 31 ] or ‘chemical coping’ [ 22 ]. Others take a broader definition integrating misuse, aberrant behaviors linked to strong opioid analgesics [ 20 ] and even addiction and dependence [ 21 ].…”
Section: Discussionmentioning
confidence: 99%
“… Risk of use disorder prevalence according to screening scale: ( a ) forest plot, ( b ) funnel plot [ 18 , 19 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 ]. …”
Section: Figurementioning
confidence: 99%
“… Risk of use disorder prevalence by sex. ( a ) Male [ 18 , 20 , 22 , 23 , 25 , 26 , 28 , 29 ]; ( b ) Female [ 18 , 20 , 22 , 23 , 25 , 26 , 28 ]. …”
Background: The opioid use disorder is an international public health problem. Over the past 20 years it has been the subject of numerous publications concerning patients treated for chronic pain other than cancer-related. Patients with cancer-related pain are also at risk of opioid use disorder. The primary objective of this literature review was to determine the prevalence of opioid use disorder in patients with cancer-related chronic pain. Its secondary objective was to identify the characteristics of these opioid users. Methods: This is a literature review of studies published over the last twenty years, from 1 January 2000 to 31 December 2020 identified by searching the three main medical databases: Pubmed, Cochrane, and Embase. A meta-analysis took account of between and within-study variability with the use of random-effects models estimated by the DerSimonian and Laird method. Results: The prevalence of opioid use disorder was 8% (1–20%) and of the risk of use disorder was 23.5% (19.5–27.8%) with I2 values of 97.8% and 88.7%, respectively. Conclusions: Further studies are now needed on the prevalence of opioid use disorder in patients treated for cancer-related chronic pain. A screening scale adapted to this patient population is urgently needed.
“…The definition used varied according to the article. Some authors consider only abuse [ 18 ], misuse [ 31 ] or ‘chemical coping’ [ 22 ]. Others take a broader definition integrating misuse, aberrant behaviors linked to strong opioid analgesics [ 20 ] and even addiction and dependence [ 21 ].…”
Section: Discussionmentioning
confidence: 99%
“… Risk of use disorder prevalence according to screening scale: ( a ) forest plot, ( b ) funnel plot [ 18 , 19 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 ]. …”
Section: Figurementioning
confidence: 99%
“… Risk of use disorder prevalence by sex. ( a ) Male [ 18 , 20 , 22 , 23 , 25 , 26 , 28 , 29 ]; ( b ) Female [ 18 , 20 , 22 , 23 , 25 , 26 , 28 ]. …”
Background: The opioid use disorder is an international public health problem. Over the past 20 years it has been the subject of numerous publications concerning patients treated for chronic pain other than cancer-related. Patients with cancer-related pain are also at risk of opioid use disorder. The primary objective of this literature review was to determine the prevalence of opioid use disorder in patients with cancer-related chronic pain. Its secondary objective was to identify the characteristics of these opioid users. Methods: This is a literature review of studies published over the last twenty years, from 1 January 2000 to 31 December 2020 identified by searching the three main medical databases: Pubmed, Cochrane, and Embase. A meta-analysis took account of between and within-study variability with the use of random-effects models estimated by the DerSimonian and Laird method. Results: The prevalence of opioid use disorder was 8% (1–20%) and of the risk of use disorder was 23.5% (19.5–27.8%) with I2 values of 97.8% and 88.7%, respectively. Conclusions: Further studies are now needed on the prevalence of opioid use disorder in patients treated for cancer-related chronic pain. A screening scale adapted to this patient population is urgently needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.